CyDex Pharmaceuticals, Inc. develops and licenses Captisol, a drug formulation technology that enables new product development by improving the solubility, stability, bioavailability, and dosing of active pharmaceutical ingredients (APIs). Its Captisol drug formulation technology is designed to maximize safety by eliminating the damaging effects produced by the parent beta-cyclodextrin; and enable an aqueous formulation for va...
CyDex Pharmaceuticals, Inc. develops and licenses Captisol, a drug formulation technology that enables new product development by improving the solubility, stability, bioavailability, and dosing of active pharmaceutical ingredients (APIs). Its Captisol drug formulation technology is designed to maximize safety by eliminating the damaging effects produced by the parent beta-cyclodextrin; and enable an aqueous formulation for various water insoluble APIs as oral, nasal, topical, ophthalmic, or liquid-presented medications.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.